Previous 10 | Next 10 |
Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million - 64 percent growth year-over-year in revenues - 76 percent growth year-over-year in billable volumes - Ended the year with more than 17,500 active healthcare...
Invitae to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire SAN FRANCISCO , Jan. 5, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George , chi...
Genetic testing company Invitae (NYSE: NVTA) has seen its shares tumble from their highs despite aggressively ramping up its test volumes this year. The company is at the center of integrating genetics into healthcare, and this space still has so much potential. However, sometim...
It’s not uncommon for investors to look for cheap stocks thinking they have tremendous growth potential. However, that’s not exactly how it works. Investors need to consider a company’s market cap and how large that can get. That determines a company’s growth pot...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – December 1, 2021 – Early onset colorectal cancer is currently on the rise [ [1] ] , according to a new study [ [2] ] from the University of Colorado S...
Invitae (NYSE: NVTA) announced its third-quarter results on Nov. 8, 2021. In this Motley Fool Live video recorded on Nov. 10 , Motley Fool contributors Keith Speights and Brian Orelli discuss what especially stood out in the company's Q3 update. Continue readin...
Fulgent has benefited tremendously from its COVID-19 testing business. As we move towards an endemic COVID era, questions on Fulgent's core NGS business starts emerging. We discuss what investors should consider on Fulgent stock moving forward. For further details see: F...
The following slide deck was published by Invitae Corporation in conjunction with their 2021 Q3 earnings call. For further details see: Invitae Corporation 2021 Q3 - Results - Earnings Call Presentation
Shares fall as Q3 estimates fall well short of estimates. Yearly revenue forecast reduced despite more acquisitions. Outstanding share count surges as cash burn continues. For further details see: Invitae: New Low On Major Revenue Disappointment
Invitae Corporation (NVTA) Q3 2021 Results Conference Call November 9, 2021 04:30 PM ET Company Participants Sean George – Chief Executive Officer Roxi Wen – Chief Financial Officer Vishal Sikri – President of NVTA Oncology Rakesh Patel – Chief Medical Officer Digi...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...